Of note, overexpression of DNM2 in wild-type (WT) mice by transgenesis or adeno-associated virus creates a centronuclear myopathy (CNM) phenotype10, 11, while genetic reduction of DNM2 in the myopathic Mtm1KO mice, by crossing with Dnm2+/− heterozygous mice, prevented the development of myotubular myopathy in Mtm1KO mice9, altogether pointing to DNM2 as a target for therapeutic development. This evidence concerns the gene DNM2 and centronuclear myopathy.